Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for kidney cancer: experimental drug XmAb819 enters human testing

NCT ID NCT05433142

Recruiting now Disease control Sponsor: Xencor, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 08, 2026 · Last updated May 25, 2026 · Updated 9 times

Summary

This early-stage study tests an experimental drug called XmAb819 in people with advanced clear cell kidney cancer that has not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the drug intravenously or as an injection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Xencor Investigative Site

    RECRUITING

    Phoenix, Arizona, 85054, United States

  • Xencor Investigative Site

    RECRUITING

    Duarte, California, 91010, United States

  • Xencor Investigative Site

    RECRUITING

    Sacramento, California, 95817, United States

  • Xencor Investigative Site

    RECRUITING

    New Haven, Connecticut, 06520, United States

  • Xencor Investigative Site

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Xencor Investigative Site

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Xencor Investigative Site

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Xencor Investigative Site

    RECRUITING

    Chicago, Illinois, 60637, United States

  • Xencor Investigative Site

    RECRUITING

    Louisville, Kentucky, 40207, United States

  • Xencor Investigative Site

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Xencor Investigative Site

    RECRUITING

    New Brunswick, New Jersey, 088901, United States

  • Xencor Investigative Site

    RECRUITING

    New York, New York, 10032, United States

  • Xencor Investigative Site

    RECRUITING

    New York, New York, 10065, United States

  • Xencor Investigative Site

    RECRUITING

    Charlotte, North Carolina, 28777, United States

  • Xencor Investigative Site

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Xencor Investigative Site

    RECRUITING

    Cincinnati, Ohio, 45267, United States

  • Xencor Investigative Site

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Xencor Investigative Site

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

  • Xencor Investigative Site

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Xencor Investigative Site

    RECRUITING

    Seattle, Washington, 98109, United States

  • Xencor Investigative Site

    RECRUITING

    Villejuif, 94805, France

  • Xencor Investigative Site

    RECRUITING

    Madrid, 28050, Spain

  • Xencor Investigative Site

    RECRUITING

    Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

Conditions

Explore the condition pages connected to this study.

CLEAR CELL RENAL CELL CARCINOMA